Feb. 11, 2014 17:00 UTC

Antibody Drug Conjugates: Contract Manufacturing Market to Evolve Rapidly, Predicts Roots Analysis

LONDON--(BUSINESS WIRE)-- Roots Analysis has announced the addition of the “Antibody Drug Conjugates: Contract Manufacturing Market, 2014-2024” report to their offering. The report provides an extensive study of the contract manufacturing opportunity for this emerging class of therapeutics. It identifies various CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical/commercial) for bio-conjugation and geographic location/spread of the facilities.

Shivani Singh, the principal analyst, said, “The multi-component aspect of ADCs deems it necessary to have both biologic and high-potency facilities. Despite the fact that this new class of therapeutic agents is gaining increased attention, in-house manufacturing of these molecules is rare.

“Most of the companies have a limited number of ADCs under development. Considering that utilization rates are likely to be low in the near future, the investment required for setting up in-house high-containment biologic facilities is a huge financial risk. As such, the majority of the work is currently being outsourced.”

The report examines insights gathered from secondary research and/or interviews of over 100 companies. Examples of companies which were interviewed include:

  • Piramal Healthcare
  • Lonza
  • Catalent
  • BSP Pharmaceuticals

There has been a surge in investments from CMOs for facility expansions during the last one year. Although there are only three marketed ADCs to date (including Mylotarg), a rich and growing pipeline offers a big opportunity for contract manufacturers. Roots Analysis predicts that the size of this opportunity is likely to be more than USD 1 billion in the near future. The detailed market forecast is based on the analysis of:

  • ADC therapeutics pipeline
  • In-house/contract manufacturing status of phase II, phase III and marketed ADCs
  • Commercial sales potential of molecules under development
  • Likely outsourcing profile across various steps involved in manufacturing

Who will benefit from this report?

This research is targeted towards pharma companies and CMOs working in the field of ADCs. In particular, you could benefit if you are an:

  • Investor
  • Contract manufacturer
  • R&D Manager
  • Business Intelligence / Scientific Analyst
  • Licensing / Portfolio Manager
  • Strategy Manager

For additional details and/or to request sample pages, please visit http://www.rootsanalysis.com/reports/view_document?report_id=46 or email at sales@rootsanalysis.com.

The company did another comprehensive research project on the ADC market in 2013. The details of this study can be found at http://www.rootsanalysis.com/reports/view_document?report_id=21.


Roots Analysis
Gaurav Chaudhary

Source: Roots Analysis